Iatrogenic immunosuppression and cutaneous malignancy.
| Autor: | DePry JL; Kansas City University of Medicine and Biosciences, 1750 Independence Ave, Kansas City, MO 64106, USA., Reed KB, Cook-Norris RH, Brewer JD |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinics in dermatology [Clin Dermatol] 2011 Nov-Dec; Vol. 29 (6), pp. 602-13. |
| DOI: | 10.1016/j.clindermatol.2011.08.009 |
| Abstrakt: | Patients with autoimmune and inflammatory conditions often receive long-term immunosuppressive therapy. Some of the largest patient populations with iatrogenic immunosuppression include patients who have received solid-organ transplants or who have rheumatoid arthritis or psoriasis. Although treatments improve patient outcomes, individuals with immunosuppression subsequently may have an increased risk of skin cancer, including squamous cell carcinoma, basal cell carcinoma, and malignant melanoma. (Copyright © 2011 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect